

Preclinical Safety Evaluation of TCR-T Cell Products for Advanced Ovarian Cancer



PRINCIPAL INVESTIGATORS/COLLABORATORS

Ebru Coskun

Sebastian Ochsenreiter

Charité Comprehensive Cancer Center

ATMP

Oncology

SUMMARY

Ovarian cancer bears the highest mortality rate amongst gynecological malignancies with epithelial ovarian cancer (EOC) causing approximately 200 000 deaths annually.

There is a high unmet medical need as this „cold“ tumor does not respond to immunotherapy such as checkpoint inhibitors. TCR-T therapies have shown promise in the solid tumor setting.

The team aims to develop a novel TCR-T cell product for the treatment of EOC.

PROJECT GOALS

- Identification and characterization of TCR construct.
- Safety and off-target evaluation.
- Patent filing.

LONG-TERM GOALS

- Out-licensing of patent.
- Transfer to other tumor entities as soon as approach is implemented for EOC.